Background-Idiopathic pulmonary arterial hypertension (IPAH) is a cardiopulmonary disease characterized by cellular proliferation and vascular remodeling. A more recently recognized characteristic of the disease is the dysregulation of glucose metabolism. The primary link between altered glucose metabolism and cell proliferation in IPAH has not been elucidated. We aimed to determine the relationship between glucose metabolism and smooth muscle cell proliferation in IPAH. Methods and Results-Human IPAH and control patient lung tissues and pulmonary artery smooth muscle cells (PASMCs) were used to analyze a specific pathway of glucose metabolism, the hexosamine biosynthetic pathway. We measured the levels of O-linked β-N-acetylglucosamine modification, O-linked β-N-acetylglucosamine transferase (OGT), and O-linked β-N-acetylglucosamine hydrolase in control and IPAH cells and tissues. Our data suggest that the activation of the hexosamine biosynthetic pathway directly increased OGT levels and activity, triggering changes in glycosylation and PASMC proliferation. Partial knockdown of OGT in IPAH PASMCs resulted in reduced global O-linked β-Nacetylglucosamine modification levels and abrogated PASMC proliferation. The increased proliferation observed in IPAH PASMCs was directly impacted by proteolytic activation of the cell cycle regulator, host cell factor-1. Conclusions-Our data demonstrate that hexosamine biosynthetic pathway flux is increased in IPAH and drives OGTfacilitated PASMC proliferation through specific proteolysis and direct activation of host cell factor-1. These findings establish a novel regulatory role for OGT in IPAH, shed a new light on our understanding of the disease pathobiology, and provide opportunities to design novel therapeutic strategies for IPAH. 
I
diopathic pulmonary arterial hypertension (IPAH) is a rapidly progressive disease with poor prognosis that affects the heart and lungs. [1] [2] [3] [4] Presently, IPAH is considered a vasculopathy that results from the structural and morphological changes of the vasculature within the lung. Altered metabolic functions, including dysregulated glucose uptake/metabolism have been described in IPAH [5] [6] [7] and have the potential to impact several key processes implicated in the pathogenesis of the disease, including cellular proliferation. Understanding the molecular mechanisms and pathways that link dysregulation in glucose metabolism to cell proliferation can lead to a better understanding of the disease and the development of novel IPAH therapies.
Clinical Perspective on p 1268
The hexosamine biosynthetic pathway (HBP) serves as a sensor for metabolic flux and is a precursor for glycosylation pathways. [8] [9] [10] Once activated, the HBP generates the sugar nucleotide UDP-N-acetylglucosamine (UDP-GlcNAc), which is a substrate for hyaluronan (HA) and CMP-sialic acid synthesis, and for the O-linked β-N-acetylglucosamine (O-GlcNAc) modification of proteins. 11 O-GlcNAc modification is a cellular process similar, and often reciprocal, to protein phosphorylation with occupation of the same serine/threonine residues when the phosphate is removed. 12 Typically, O-GlcNAc modification has an inverse functional relationship with phosphorylation and is important in the regulation of the target protein's function. 13 In the presence of UDP-GlcNAc, transfer of the GlcNAc moiety to serine and threonine residues within proteins is governed by the O-GlcNAc transferase (OGT). 14, 15 Conversely, the removal of the residue is governed by the cytosolic or nuclear β-N-acetylglucosaminidase (O-GlcNAc hydrolase, OGA). 16, 17 Recently, OGT was recognized for its dual role in the hyper O-GlcNAc modification and subsequent proteolytic activation of the cell cycle master regulator, host cell factor-1 (HCF-1), indicating a direct role for OGT in cell proliferation. 18, 19 Indeed, OGT synergizes with the HBP to regulate both nuclear and cytoplasmic protein functions through the O-GlcNAc modification.
We previously demonstrated increased levels of HA in plasma and tissues in IPAH patients, 20 suggesting augmented glucose flux through the HBP to increase UDP-GlcNAc, a substrate for HA synthesis. However, the functional role of the HBP and the underlying mechanisms of IPAH pulmonary artery smooth muscle cell (PASMC) proliferation have not been determined. We hypothesized that IPAH is characterized by increased HBP flux and OGT upregulation, which promotes and perpetuates PASMC proliferation. We report here that HBP flux is indeed enhanced in IPAH, and OGT levels and activity are increased. Together, these changes promote protein glycosylation leading to PASMC proliferation. The increased proliferation observed in IPAH PASMCs is directly impacted by the OGT activation of HCF-1, a phenomenon recently described in proliferating cancer cells. 18 These new insights into the mechanism of PASMC proliferation can lead to the identification of novel therapeutic targets in IPAH.
Materials and Methods

Lung Tissue, PASMC Isolation, and Culture Conditions
All explanted lungs were collected either at the Cleveland Clinic through an institutional review board-approved protocol or they were provided by Baylor, Stanford, Vanderbilt, University of Alabama, and Allegany College of Maryland under the Pulmonary Hypertension Breakthrough Initiative. Funding for the Pulmonary Hypertension Breakthrough Initiative was provided by the Cardiovascular Medical Research and Education Fund. Human lung tissues used in this study were from 8 donor lung explants not suitable for lung transplantation and 8 IPAH patients (Table 1) . Human PASMCs and pulmonary arterial endothelial cells were isolated from elastic pulmonary arteries dissected from both control and IPAH lungs obtained at explantation (Table 1 ) by using a previously described method. 21 In brief, human pulmonary arteries were minced and digested overnight in Hanks balanced salt solution containing collagenase and DNase and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffer (Sigma, St. Louis, MO). On the removal of the pulmonary arterial endothelial cells, smooth muscle cells were released from the artery tissue, filtered with a 100-μm-pore nylon cell strainer (BD Falcon, Bedford, MA), cultured in Dulbecco modified Eagle medium/nutrient mixture F-12 medium supplemented with 10% fetal bovine serum (BioWhittaker, Walkersville, MD) and antibiotics, and incubated at 37°C, 5% CO 2 with 90% humidity followed by media changes at 24 hours and every 4 days until confluence. The PASMCs were confirmed routinely through positivity staining for α-smooth muscle cell actin (Sigma/Aldrich, St. Louis, MO).
Immunohistochemistry, Immunofluorescence, and Hematoxylin and Eosin Stains
For additional methods, see Materials and Methods in the online-only Data Supplement.
Sample Preparation and Western Blotting
Frozen human lung tissue 20 and PASMCs 22 were prepared as previously described with O-(2-acetamido-2-deoxy-dglucopyranosylidenamino) N-phenylcarbamate (50 µmol/L; Sigma, St. Louis, MO) + Thiamet G (25 nmol/L, Sigma) added to block removal of the O-GlcNAc modification and subjected to Western blot analysis. Nitrocellulose membranes were probed with antisera for the following: (1) O-GlcNAc (1:1000; clone CTD 110.6, generous gift from the laboratory of Dr Gerald Hart) and HCF-1 (1:1000; Abcam, Cambridge, MA) probed blots were developed by using enhanced chemiluminescence (Amersham, Pittsburgh, PA), and (2) blots probed for glutamine:fructose-6-phosphate aminotransferase-1 (1:2000; Abcam, Cambridge, MA), OGT (1:5000, Hart Laboratory), OGA (1:5000 Hart Laboratory), β-actin (1:10 000; Santa Cruz, CA), glucose transporter 1 (GLUT1; 1:2000; Millipore, Billerica, MA) and glucose transporter 4 (GLUT4; 1:2000; Millipore) were blocked, washed, and imaged by using an Odyssey Infrared Imaging System (Li-Cor Biosciences, Lincoln, NE).
Fluorophore-Assisted Carbohydrate Electrophoresis UDPSugar Analysis
PASMCs were washed, collected, and centrifuged in cold phosphatebuffered saline. Cells were fixed with 75% cold ethanol, sonicated, and subjected to fluorophore-assisted carbohydrate electrophoresis analysis (see online-only Data Supplement Materials and Methods).
siRNA Transfection and OGT Inhibitor Experiments
PASMCs were subjected to small interfering RNA (siRNA) knockdown with a scrambled, an antisense siRNA oligonucleotide against OGT, or an OGT-specific inhibitor (see online-only Data Supplement Materials and Methods).
Cell Proliferation and Flow Cytometry Analysis
PASMCs were pulsed for 2 hours with 10 µmol/L 5-bromo-2′-deoxyuridine (Sigma, St. Louis, MO) and subjected to flow cytometric analysis (see online-only Data Supplement Materials and Methods). The gating strategy and the relevant controls for flow cytometric analysis are shown in Figure I in the online-only Data Supplement.
Study Population for Erythrocyte Collection
Patients were recruited from the Pulmonary Vascular Program at Cleveland Clinic. Blood was drawn from patients and deposited into our biorepository. Demographic and clinical characteristics of the individuals who have pulmonary arterial hypertension (PAH) are listed in Table 2 . Pulmonary hypertension was confirmed by right heart catheterization. PAH categories were identified based on the updated clinical classification of pulmonary hypertension. 23 Healthy controls were defined as patients with no history of pulmonary/cardiac disease or symptoms. All participants signed a consent form that was approved by the Cleveland Clinic Institutional Review Board before participation in the study.
Erythrocyte Experiments and Western Blotting Procedures
An initial set of human PAH (n=9) and control (n=9) red blood cells (RBCs) were lysed, and hemoglobin was depleted by using a procedure described previously 24 to compare the levels of O-GlcNAc (CTD 110.6, Hart Laboratory) and OGT (Hart Laboratory) by Western blot analysis. OGT and the O-GlcNAc modification were normalized to β-actin and quantitated by using ImageJ 25 software.
OGT Association With Clinical Outcomes by Using PAH RBCs
PAH RBC hemoglobin depleted lysates (n=86) were subjected to Western blot analysis to determine the levels of OGT for each patient. After quantitation, OGT levels were correlated to clinical parameters of disease severity, including the functional class, walk distance, brain natriuretic peptide levels, echocardiographic parameters (right ventricular dilation and dysfunction, pericardial effusion), and hemodynamic measurements. Data were obtained from the Institutional Review Board-approved Cleveland Clinic Pulmonary Hypertension registry. Clinical events were ascertained since the time of venous blood sampling by review of medical records and query of the Social Security Death index. During the median follow-up of 24.5 months (interquartile range, 9-58.3) there were 38 hospitalizations, 3 lung transplantations, and 1 death. However, hospitalizations were the earliest event for the death and transplant events, so the total number of events for the analysis was 38.
Statistical Analysis
Summary statistics reported for continuous variable are mean±standard error of mean or median (25th, 75th percentiles), with the latter used for skewed distributions. Two-group comparisons with respect to continuous variables were compared with the Wilcoxon rank sum test. A P value of ≤0.05 was considered as significant, except when comparisons were performed as multiple comparisons among more than 2 groups, in which case a Bonferroni correction was used to adjust for the number of primary 2-group comparisons. Given the anticipated skewed distribution of OGT levels, its associations with continuous clinical parameters were assessed by using the Spearman correlation coefficient, and its associations with categorical parameters were assessed by using the Wilcoxon test. We also investigated the association between OGT levels and clinical worsening (defined as disease-related hospitalizations, lung transplantation, or all-cause mortality) inferentially by using Cox proportional hazard models with respect to OGT in its continuous form, and descriptively using Kaplan-Meier curves. All statistical analysis was done using JMP version 10.0.0 for Microsoft Windows or R version 3.0.1 (www.R-project.org).
Results
Glycosylation Changes in the Pulmonary Vasculature of IPAH Patients
To determine if altered glycosylation is observed in IPAH, we stained tissues from control and IPAH-explanted lungs with wheat-germ agglutinin, a lectin that specifically recognizes N-acetylglucosamine (GlcNAc) and sialic acid. IPAH tissues had an increased intensity of wheat-germ agglutinin lectin staining suggesting changes in glycosylation ( Figure 1A and 1B and Figure II in the online-only Data Supplement). The increased glycosylation was much more evident in the occluded pulmonary vessels and plexogenic lesions in IPAH than in control tissues ( Figure 1A through 1D). These data indicate that glycosylation changes are prominent in IPAH.
HBP Flux in IPAH
Because IPAH has increased HA levels and altered glycosylation, we examined the activation state of the HBP. As shown in Figure 1E and 1F, glutamine:fructose-6-phosphate aminotransferase-1, the HBP rate-limiting enzyme, was increased in IPAH lung tissue (control, 8.2±7.0; IPAH, 28.1±12.4, P=0.002). A similar finding was determined in IPAH PASMCs isolated from the lung explants ( Figure 1G and 1H, glutamine:fructose-6-phosphate aminotransferase-1: control, 4.1±1.2; IPAH, 7.1±2.0, P=0.02). Importantly, UDP-GlcNAc pools were reduced in IPAH PASMCs in comparison with controls ( Figure 1I ; control, 103.7±34.0; IPAH, 46.1±17.8, P=0.04). Collectively, these data suggest that the HBP is augmented in IPAH.
Global Increase in OGT-Facilitated O-GlcNAc Modification of Proteins in Human IPAH Lungs and PASMCs
To Data are presented as mean±standard deviation (except for BNP where the data are presented as median (25th and 75th percentile) or number (%) as appropriate. BNP indicates B-type natriuretic peptide; CHD, congenital heart disease; CTD, connective tissue disease; CI, cardiac index; 6MWD, 6-minute walk distance; mPAP, mean pulmonary artery pressure; NYHA, New York Heart Association; PAH, pulmonary arterial hypertension; PVR, pulmonary vascular resistance; RAP, right atrial pressure; and RBC, red blood cell. Immunohistochemical staining for the O-GlcNAc modification of proteins within the lung tissue validated the increased O-GlcNAc levels observed in IPAH patients (Figure 2A-2H ). Higher magnification of the lung tissue revealed increased O-GlcNAc staining within the pulmonary vasculature (including plexogenic lesions) of IPAH patients in comparison with controls (Figure 2A-2H ). These findings are consistent with our wheat-germ agglutinin lectin stains ( Figure 1A and 1B) and immunoblot data ( Figure 1J-1L) , suggesting increased glycosylation events within IPAH lung tissue.
Because the O-GlcNAc modification was more prevalent in the thickened tunica media of the pulmonary arteries in IPAH, we investigated the nature of this region by using primary IPAH PASMCs isolated from explanted lungs. Western blot analysis determined that the levels of O-GlcNAc-modified proteins were also elevated in IPAH PASMCs ( Figure 2I and 2J, control, 5.7±2.1; IPAH, 9.6±2.4, P=0.01) and demonstrated consistently higher levels of OGT (Figure 2I and 2K ; control, 2.6±0.5; IPAH, 5.8±1.6, P=0.021) similar to the lung tissue observations ( Figure 1E and 1F and 1J-1L) and IPAH pulmonary arterial endothelial cell isolates ( Figure IV in the online-only Data Supplement). In addition, GLUT1 levels were elevated in the IPAH PASMCs (Figure 2I and 2L ; control, 7.4±2.3; IPAH, 10.6±3.1, P=0.03) analogous to reports indicating increased glucose uptake. 5, 26, 27 However, the insulin-sensitive transporter GLUT4 was not significantly different (Figure 2I and 2M; control, 13.1±2.9; IPAH, 14.4±2.1, P=0.56). This finding is consistent with previously published reports that described GLUT1 as the predominant transporter for glucose uptake in primary PASMCs. 28 Collectively, these findings suggest that the excessive HBP flux consequentially results in increased OGT transfer of O-GlcNAc within the IPAH pulmonary vasculature.
OGT Directs Cell Proliferation in Primary PASMCs
Next, we determined whether OGT can mediate PASMC proliferation in IPAH. We used siRNA-facilitated knockdown (KD) of OGT in IPAH PASMCs and compared with control levels. Gene silencing caused a reduction in OGT ( Figure 3A ; P=0.05, respectively). In addition, cell proliferation was assessed by cellular 5-bromo-2′-deoxyuridine incorporation, which confirmed a significant decline (Figure 3D and 3E A reduction in PAH PASMC proliferation to control levels was also determined by using an OGT inhibitor (alloxan monohydrate), consistent with the siRNA KD to OGT (Figure V in the online-only Data Supplement). These data indicate that the reduction in OGT levels results in decreased PASMC proliferation in IPAH.
Increased OGT Activates HCF-1 in IPAH PASMCs
To determine whether increased OGT expression corresponds to enhanced activity, HCF-1 cleavage, and subsequent activation in IPAH, we reduced OGT levels by siRNA KD or its activity by administration of an OGT inhibitor (TT40) in IPAH PASMCs. Reduced OGT expression resulted in a marked decrease in HCF-1 cleavage products comparable to D) occluded vessel within a plexogenic lesion from serial sections of the same lung tissue. E, Characteristic immunoblots of GFAT1, OGT, and OGA from multiple control and IPAH human tissues isolated from explant lungs (n=8). Lysates were normalized to total protein, and β-actin was used as a loading control. F, Densitometry quantitation of each protein compared to β-actin. G, GFAT1 was also probed in multiple control and IPAH human PASMCs isolated from pulmonary arteries (n= 4) and quantitated. H and I, UDP-GlcNAc pools were isolated (see Materials and Methods) and analyzed from multiple control and IPAH PASMCs (n=3). UDP-GlcNAc levels were normalized to total DNA concentration. In addition, total O-GlcNAc levels were analyzed in control (J) and IPAH (K) lung tissue. The global protein O-GlcNAc levels were normalized to β-actin (E) and quantified (L). As a reactivity control, the O-GlcNAc antibody was pretreated with 250 mmol/L GlcNAc before primary incubation ( Figure III 
OGT Associated With Clinical Worsening in PAH
Increased OGT levels have been shown to be associated with poor outcomes and disease aggressiveness in patients who have prostate cancer, 29, 30 suggesting that increased OGT activity contributes to the disease progression. In addition, a previous report screened multiple patient RBCs for changes in global O-GlcNAc, OGT, and OGA as potential indicators of disease. 24 Based on these studies, we analyzed global O-GlcNAc, OGT, and OGA levels from PAH and control RBCs by Western blot. Our initial assessment demonstrated an increase in the overall levels of OGT and O-GlcNAc in PAH RBCs in comparison with control with no significant change in OGA levels ( Figure 5A-5E ), which is consistent with Figure 1E and 1F and 1J-1L. Because OGT levels were higher in PAH RBCs, we measured OGT levels by Western blot analysis in 86 PAH RBC patient samples and associated with clinical outcomes in these patients. Data are expressed as OGT/β-actin ratios. Table 2 shows the baseline clinical characteristics of this cohort. Inverse correlations between OGT expression and right heart stroke volume (r s =-0.31, P<0.01) and the 6-minute walk distance (r s =-0.21, P<0.05) were observed. OGT was higher in patient New York Heart Association functional class III to IV symptoms in comparison with New York Heart Association class I to II (median, 0.48; interquartile range, 0.35-0.58 versus 0.36; interquartile range, 0.23-0.48, respectively; P<0.05). Finally, OGT levels were associated with a higher probability to clinical worsening ( Figure 5F ), defined as hospitalization for PAH, lung transplantation, or death (3.71; 95% confidence interval, 1.05-13.2; for an OGT/β-actin ratio ≥0.396; P=0.043 for OGT in its continuous form). These data suggest that OGT may be a useful marker of disease severity in PAH.
Discussion
IPAH is a rapidly progressive cardiopulmonary disease characterized by vasoconstriction and aberrant vascular cell proliferation. Current therapies mainly target vasoconstriction. The future of IPAH therapy, however, depends on our ability to identify and target the molecular underpinnings of cell proliferation in this devastating disease. In this report, we demonstrate that PASMC proliferation, a major component in the pathobiology of IPAH, is directed by increased HBP flux coupled with enhanced OGT activity, causing proteolytic activation of HCF-1. To our knowledge, this is the first description of altered HBP flux in IPAH resulting in global O-GlcNAc modification of proteins and direct activation of HCF-1 by OGT. IPAH shares several disease signatures with cancer, including cell proliferation and dysregulated glucose metabolism and use. 31 These changes in energy production and metabolic dysregulation are hallmarks of hyperproliferative cells. These cells disproportionately use metabolites (such as glucose and glutamine) to survive in energy-starved environments. In 1924, Otto Warburg found that highly proliferative cancer cells metabolize glucose via the less energy-efficient glycolysis pathway despite the presence of oxygen. 32 For almost a century, scientists have speculated on the reason for this phenomenon. The current consensus is that glycolysis provides not only energy, but also the building blocks required for cell proliferation. 33 Once the proliferating cells have switched to aerobic glycolysis, they produce less ATP than cells using glucose oxidation and, in turn, more rapidly take up glucose when sufficient levels are available. 34 The extensive energy requirements of highly proliferative cells often result in excess use of metabolites (namely glucose, glutamine, acetylcoenzyme A, and uridine triphosphate) through multiple pathways, including the HBP. Our studies are in agreement with this notion and suggest that the increased HBP flux observed in IPAH patients (Figures 1 and 2 ) is an effect of the metabolic switch to aerobic glycolysis observed in proliferating cells. Studies in cancer cells have demonstrated a similar role of HBP flux, OGT, and hyper O-GlcNAc modification of proteins involved in cancer cell proliferation. 30, 35, 36 Our data ( Figure 3 ) demonstrates a direct role for OGT in IPAH PASMC proliferation, which corresponds with the cancer cell reports. 30, 35, 36 As a nutrient sensor of the cell, the HBP 9,10,37 integrates the metabolism of carbohydrates, amino acids, fat, and nucleotides for the synthesis of UDP-GlcNAc, the final product of the pathway. Recently, Wellen et al 38 demonstrated that treatment of glucose-starved cells with GlcNAc (to maintain hexosamine biosynthesis) rescued cell growth, indicating the importance of the HBP in cell proliferation. The effect of the HBP on cell proliferation is most likely mediated by OGT, which uses UDP-GlcNAc for the O-GlcNAc modification of proteins. This finding is consistent with the observed low levels of UDPGlcNAc determined in the IPAH patients (Figure 1 ) in our study despite the increased HBP flux and glutamine:fructose-6-phosphate aminotransferase-1 protein expression.
Modulating O-GlcNAc levels has already been shown in cancer cells to contribute to cancer cell survival, proliferation, and metastasis. 30, 39 OGT, through protein O-GlcNAc modification, can control many cellular events including cell cycle, 12 transcription, 40 signal transduction, 41 nutrient sensing, 10 and cell stress responses. 42 Interestingly, OGT can also effect cell proliferation through a completely different and distinct mechanism. Herr and colleagues 18, 19 recently demonstrated that OGT specifically cleaves the precursor form of the cell cycle master regulator, HCF-1. On cleavage by OGT, the N-terminal and C-terminal subunits of HCF-1 are functionally activated 18 and facilitate G1 phase cell cycle progression, 43 and mitosis and cytokinesis, as well. 44 In line with these findings, our data suggest that cleavage of HCF-1 is directly facilitated by OGT in IPAH (Figure 4 ) and represents the first evidence for this phenomenon in a disease other than cancer. Moreover, this result underscores a more direct involvement of OGT in the cell proliferation process. Although the HBP and O-GlcNAc have been implicated in pathogenesis of other noncancerous diseases including heart disease, [45] [46] [47] type 2 diabetes mellitus, 41, [48] [49] [50] [51] and insulin resistance. 37, 52 In addition, increased OGT levels have been shown to be associated with poor outcomes and disease persistence in patients with prostate cancer, 29, 30 suggesting that the increased O-GlcNAc protein modification contributes to the disease progression. However, these findings have not been previously reported in IPAH. We found increased HBP flux, elevated OGT, and global O-GlcNAc modification of proteins in IPAH. In particular, we observed increased OGT and O-GlcNAc levels in RBCs of PAH patients ( Figure 5 ), which is similar to the results from the IPAH lung (Figure 1) . Also, we showed that increased OGT levels in RBCs are associated with poor PAH clinical outcomes ( Figure 5 ). These data suggest that OGT levels from RBCs may be useful to gauge the severity of PAH. More importantly, the altered OGT and O-GlcNAc levels observed in PAH RBCs and lung suggests that the metabolic changes may be a systemic phenomenon. Others have reported glucose intolerance, insulin resistance, and metabolic dysregulation in PAH 2, 6, [53] [54] [55] consistent with the notion that IPAH patients may have systemic metabolic derangements. In 1 report, Pugh et al 6 demonstrated that higher hemoglobin A1c levels correlated with the 6-minute walk test for IPAH patients. Thus, it is possible that our findings may be related to or a consequence of the well-documented dysregulation of glucose metabolism in this disease. Still, more research is needed to determine the systemic nature of the dysregulated metabolism in IPAH.
Fundamentally, this report demonstrates OGT as (1) an activator of HCF-1 and (2) a regulator of cell proliferation in IPAH. These findings in IPAH, along with published findings in cancer, collectively demonstrate a direct role for OGT in linking nutrient sensing of the HBP to cell cycle progression and proliferation, which may have clinical implications for a wide array of diseases beyond IPAH, including cardiovascular disease, cancer, and diabetes mellitus.
Combining the previous reports on the characterization of HA in IPAH 20, 22 along with the observations described here in this report, we put forth a model whereby an activated HBP regulates PASMC proliferation in IPAH as outlined in Figure 6 . This model establishes a regulatory role for OGT in IPAH, sheds a new light on our understanding of the disease pathobiology, and provides opportunities to design novel therapeutic strategies for IPAH. 
